Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
OBJECT: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of...
Main Authors: | Testa, L, Van Gaal, W, Bhindi, R, Biondi-Zoccai, G, Abbate, A, Agostoni, P, Porto, I, Andreotti, F, Crea, F, Banning, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis.
by: Testa, L, et al.
Published: (2008) -
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
by: Testa, L, et al.
Published: (2009) -
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
by: Testa, L, et al.
Published: (2010) -
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
by: Testa, L, et al.
Published: (2010) -
The hurdles of translating a single-center observation into practice.
by: Testa, L, et al.
Published: (2008)